Sector guide

R&D tax credits for life sciences.

From medical-device makers to digital-health and biotech teams, UAE life-sciences companies are resolving real scientific uncertainty. Some of that work can qualify for the R&D Tax Credit. The discipline is proving precisely which part.

Life Science, Biotech & HealthTech
01 · The five criteria, in life sciences

How qualifying R&D shows up in life sciences.

The UAE regime tests every project against five conditions in Ministerial Decision No. 24 of 2026, Article 3(1), assessed with regard to the OECD Frascati Manual. Here is what each looks like in a device, an assay or a clinical algorithm.

1

Novel

A device, method or therapy aimed at new scientific knowledge.

2

Creative

Original hypotheses, not routine application of known technique.

3

Uncertain

Whether a mechanism, device or method works is genuinely unknown.

4

Systematic

Planned, documented experiments and validation.

5

Transferable

Results reproducible and generalisable, not one-off.

02 · Example projects

The kind of work that qualifies.

Illustrative projects across medical devices, diagnostics and health data. Eligibility is always confirmed project by project.

Devices

Medical device development

A medical device whose design or performance cannot be reached with established methods.

Digital health

Clinical-grade algorithms

A digital-health algorithm validated to clinical performance on new data.

Therapeutics

Formulation & bioprocess

Formulation or bioprocess work to make a therapy stable, scalable or deliverable.

Diagnostics

Novel assays

Assay or biomarker development where the method itself is uncertain.

Data

Health data integration

Integrating clinical and genomic data in ways existing platforms cannot support reliably.

Regulatory

Design for approval

Engineering a device or process to meet a regulatory bar that demands genuine technical development.

03 · Where the line falls

Genuine R&D, not routine engineering.

The value we add is drawing this line correctly claiming what qualifies, and defending it, while leaving out what does not.

Typically qualifies
  • Resolving scientific uncertainty about whether a device, method or therapy works.
  • Systematic experimentation, validation and iteration.
  • Formulation, bioprocess or assay development with uncertain outcomes.
  • Engineering clinical-grade performance beyond current capability.
typically doesn't
  • Routine clinical administration and standard trial logistics.
  • Applying an established, validated method without uncertainty.
  • Cosmetic changes to an existing, approved device.
  • Market access and reimbursement analysis with no technical uncertainty.
Track record

AED 396M+

ICAEW Chartered Accountants,  AED 396M+ (£80M+) in R&D incentives secured in the UK 1,300+ R&D claims processed (UK practice) – including medical devices, diagnostics, biotech and digital health. The same chartered method now applies to the UAE.

“Simplified the R&D claim process completely. Their expertise in life sciences made all the difference.”

Ducentis BioTherapeutics life sciences client

We are preparing UAE pre-approval submissions through TAWWER now. UAE outcomes will be published here as claims complete, subject to client consent.

04 · Common questions

The administration and logistics of a standard trial usually do not. But experimental work to resolve scientific uncertainty – whether a mechanism, device or method actually works – frequently does. We separate the two carefully.

It depends on the uncertainty. Building a clinical-grade algorithm whose performance is genuinely unknown can qualify; standard application development around it does not.

The paperwork itself is not. But engineering a device or process to meet a regulatory performance bar, where achieving it required uncertain technical development, can form part of a qualifying project.

 

Contemporaneous records: the scientific uncertainty, the experiments and validation done to resolve it, and project-level cost and staff-time allocation. We build this as the work happens – and Council pre-approval through the TAWWER platform is mandatory before claiming. Applications are submitted via TAWWER, accessed with UAE PASS and authorised by the signatory registered with the Federal Tax Authority. As at 27 October 2026, calendar-year 2026 companies must apply within 40 business days of 31 December 2026, which is 26 February 2027. Work already under way can be included if it was recorded as it happened.

 

Making things here? Let’s find what qualifies.

We assess your projects against the five criteria, prepare and file your TAWWER pre-approval submission with the Council, and build the evidence before a single figure is claimed.

Book a Consultation

A few details is all we need to start.
We reply within one business day. Your details are handled in confidence.